Telaprevir for Chronic HCV Infection REPLY

被引：0
|
作者：
McHutchison, John [1 ]
Pawlotsky, Jean-Michel [2 ]
Zeuzem, Stefan [3 ]
机构：
[1] Duke Univ, Durham, NC 27715 USA
[2] Henri Mondor Univ Hosp, F-94010 Creteil, France
[3] JW Goethe Univ Hosp, D-60590 Frankfurt, Germany
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2009年 / 361卷 / 05期
关键词：
HEPATITIS-C;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：534 / 535
页数：2
相关论文
共 50 条
  • [1] Telaprevir for retreatment of HCV infection: review of the REALIZE trial
    Kim, Edward
    Chen, Yuan
    Yoshida, Eric M.
    FUTURE VIROLOGY, 2012, 7 (05) : 435 - 440
  • [2] Telaprevir for the treatment of chronic hepatitis C infection
    Muir, Andrew J.
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2011, 9 (12) : 1105 - 1114
  • [3] Patterns of viral load decline with telaprevir-based therapy in patients with genotype 1 chronic HCV infection
    Picchio, Gaston
    De Meyer, Sandra
    Dierynck, Inge
    Ghys, Anne
    Gritz, Linda
    Kieffer, Tara L.
    Bartels, Douglas J.
    Witek, Jim
    Bengtsson, Leif
    Luo, Donghan
    Kauffman, Robert S.
    Adda, Nathalie
    Sarrazin, Christoph
    JOURNAL OF CLINICAL VIROLOGY, 2014, 59 (03) : 148 - 155
  • [4] Retreatment of Chronic Hepatitis C Infection with Telaprevir : Turkey Experience
    Pekgoz, Murat
    Gurel, Selim
    Kiyici, Murat
    Gulten, Macit
    Dolar, Enver
    Nak, Selim Giray
    ACTA GASTRO-ENTEROLOGICA BELGICA, 2016, 79 (01) : 18 - 22
  • [5] Optimal treatment with boceprevir for chronic HCV infection
    Maasoumy, Benjamin
    Manns, Michael P.
    LIVER INTERNATIONAL, 2013, 33 : 14 - 22
  • [6] Reply to: "Neuroinflammation in HCV-infection - Peril or protection?"
    Byrnes, Valerie
    Lowry, Damien
    Alsop, David
    Afdhal, Nezam H.
    JOURNAL OF HEPATOLOGY, 2012, 57 (04) : 923 - 924
  • [7] Is LDLT appropriate for patients with chronic HCV infection?
    Trotter, James F.
    Jensen, Geoffrey S.
    NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY, 2008, 5 (02): : 76 - 77
  • [8] Influence of low-density lipoprotein cholesterol on virological response to telaprevir-based triple therapy for chronic HCV genotype 1b infection
    Ogawa, Eiichi
    Furusyo, Norihiro
    Kajiwara, Eiji
    Nomura, Hideyuki
    Dohmen, Kazufumi
    Takahashi, Kazuhiro
    Nakamuta, Makoto
    Satoh, Takeaki
    Azuma, Koichi
    Kawano, Akira
    Tanabe, Yuichi
    Kotoh, Kazuhiro
    Shimoda, Shinji
    Hayashi, Jun
    ANTIVIRAL RESEARCH, 2014, 104 : 102 - 109
  • [9] Progression of HCV infection in patients with chronic kidney disease
    Cholongitas, Evangelos
    Manousou, Pinelopi
    Samonakis, Dimitrios
    Burroughs, Andrew K.
    JOURNAL OF HEPATOLOGY, 2009, 50 (03) : 621 - 622
  • [10] Safety profile of boceprevir and telaprevir in chronic hepatitis C: Real world experience from HCV-TARGET
    Gordon, Stuart C.
    Muir, Andrew J.
    Lim, Joseph K.
    Pearlman, Brian
    Argo, Curtis K.
    Ramani, Ananthakrishnan
    Maliakkal, Benedict
    Alam, Imtiaz
    Stewart, Thomas G.
    Vainorius, Monika
    Peter, Joy
    Nelson, David R.
    Fried, Michael W.
    Reddy, K. Rajender
    JOURNAL OF HEPATOLOGY, 2015, 62 (02) : 286 - 293
12345